Go to the profile of Halozyme Therapeutics

Halozyme Therapeutics

 
  • United States of America

About Halozyme Therapeutics

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, investigational drug PEGPH20 (pegvorhyaluronidase alfa), applies a unique approach to targeting solid tumors, potentially providing increased immune response and tumor access for co-administered anti-cancer therapies.

Therapeutic Areas

Oncology

Technologies

Other

Company Type

Biotechnology – R&D services

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

March 2018